Biodistribution and predictive value of 18F- fluorocyclophosphamide in mice bearing human breast cancer xenografts

Journal of Nuclear Medicine

Volumn 48, Issue 12, 2007, Pages 2021-2027

  Kesner, Amanda L ^a   Hsueh, Wei Ann ^a   Htet, Nwe Linn ^a   Pio, Betty S ^a   Czernin, Johannes ^a   Pegram, Mark D ^a   Phelps, Michael E ^a   Silverman, Daniel H S ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UCLA MEDICAL CENTER   (United States)

Author keywords

18F; Breast cancer; Breast tumor therapy; Cyclophosphamide; Positron emission tomography; Prognostic imaging; Small animal imaging

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROCYCLOPHOSPHAMIDE F 18; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG UPTAKE; FEMALE; IN VIVO STUDY; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; SYNTHESIS; TREATMENT RESPONSE; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CYCLOPHOSPHAMIDE; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 36849001220     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.107.045716     Document Type: Article

References (39)

1. Calabresi P, Welch AD. Chemotherapy of neoplastic diseases. Annu Rev Med. 1962;13:147-202.
2. Engert A, Wolf J, Diehl V. Treatment of advanced Hodgkin's lymphoma: standard and experimental approaches. Semin Hematol. 1999;36:282-289.
3. Diehl V, Franklin J, Hasenclever D, et al. BEACOPP: a new regimen for advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group. Ann Oncol. 1998;9(suppl 5):S67-S71.
4. Walters TR. The definitive treatment of children with acute leukemia. Med Clin North Am. 1976;60:987-1000.
5. Cheung NV, Heller G. Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma. J Clin Oncol. 1991;9:1050-1058.
6. Abrams JS. North American adjuvant breast cancer trials. Recent Results Cancer Res. 1998;152:417-428.
7. Ludeman SM. The chemistry of the metabolites of cyclophosphamide. Curr Pharm Des. 1999;5:627-643.
8. Malet-Martino M, Gilard V, Martino R. The analysis of cyclophosphamide and its metabolites. Curr Pharm Des. 1999;5:561-586.
9. Sreerama L, Sladek NE. Primary breast tumor levels of suspected molecular determinants of cellular sensitivity to cyclophosphamide, ifosfamide, and certain other anticancer agents as predictors of paired metastatic tumor levels of these determinants. Cancer Chemother Pharmacol. 2001;47:255-262.
10. Sladek NE, Kollander R, Sreerama L, Kiang DT. Cellular levels of aldehyde dehydrogenases (aldh1a1 and aldh3a1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study - rational individualization of oxazaphosphorine-based cancer chemotherapeutic regimens. Cancer Chemother Pharmacol. 2002;49:309-321.
11. Gamcsik MP, Dolan ME, Andersson BS, Murray D. Mechanisms of resistance to the toxicity of cyclophosphamide. Curr Pharm Des. 1999;5:587-605.
12. Wu L, Tannock IF. Repopulation in murine breast tumors during and after sequential treatments with cyclophosphamide and 5-fluorouracil. Cancer Res. 2003;63:2134-2138.
13. Teicher BA, Herman TS, Holden SA, et al. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science. 1990;247:1457-1461.
14. Teicher BA, Kakeji Y, Ara G, Herbst RS, Northey D. Prostate carcinoma response to cytotoxic therapy: in vivo resistance. In Vivo. 1997;11:453-461.
15. Kobayashi H, Man S, Graham CH, Kapitain SJ, Teicher BA, Kerbel RS. Acquired multicellular-mediated resistance to alkylating agents in cancer. Proc Natl Acad Sci USA. 1993;90:3294-3298.
16. Begg AC, Smith KA. A bioassay for cyclophosphamide in blood, lung and tumour. Br J Cancer. 1984;49:49-55.
17. Houghton PJ, Tew KD, Taylor DM. Some studies on the distribution and effects of cyclophosphamide (nsc-26271) in normal and neoplastic tissue. Cancer Treat Rep. 1976;60:459-464.
18. Sladek NE. Aldehyde dehydrogenase-mediated relative insensitivity to the oxazaphosphorines. Curr Pharm Des. 1999;5:607-625.
19. 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med. 2001;42:9-16.
20. Dehdashti F, Mortimer JE, Siegel BA, et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med. 1995;36:1766-1774.
21. Mintun MA, Welch MJ, Siegel BA, et al. Breast cancer: PET imaging of estrogen receptors. Radiology. 1988;169:45-48.
22. Nieweg OE. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer. 1993;71:3920-3925.
23. 18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res. 1996;2:933-939.
24. Smith IC, Gilbert FJ. Role of positron emission tomography in the management of breast cancer. Breast. 1999;8:303-310.
25. Silverman DH, Hoh CK, Seltzer MA, et al. Evaluating tumor biology and oncological disease with positron-emission tomography. Semin Radiat Oncol. 1998;8:183-196.
26. Saunders C, Dussek J, O'Doherty J. Evaluation of fluorine-18- fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer. Ann Thorac Surg. 1999;67:790-797.
27. Abdel-Nabi H, Doerr RJ, Lamonica DM, et al. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histologic and CT findings. Radiology. 1998;206:755-760.
28. Schirrmeister H, Kuhn T, Guhlmann A, et al. Fluorine-18 2-deoxy-2-fluoro-d-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med. 2001;28:351-358.
29. 18F-Labeled radiopharmaceuticals for PET in oncology, excluding FDG. Nucl Med Biol. 2000;27:103-112.
30. 18F-FDG PET. J Nucl Med. 2005;46:1144-1150.
31. Pio BS, Park CK, Pietras R, et al. Usefulness of 3′-[F-18] fluoro-3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol. 2006;8:36-42.
32. Takeuchi N, Fukumoto M, Nishioka A, et al. Scintigraphic prediction of response to chemotherapy in patients with breast cancer: technetium 99m-tetrofosmin and thallium-201 dual single photon emission computed tomography. Int J Oncol. 2002;20:53-58.
33. 18F-fluorocyclophosphamide), a potential tracer for breast tumor prognostic imaging with PET. J Labelled Comp Radiopharm. 2005;48:635-643.
34. Papanastassiou Z, Bruni J, Potts Fernandes F, Levins P. Potential carcinolytic agents. III. Fluoronitrogen mustard analogs of cyclophosphamide. J Med Chem. 1966;9:357-359.
35. Gutman M, Couillard S, Labrie F, Candas B, Labrie C. Effects of the antiestrogen em-800 (sch 57050) and cyclophosphamide alone and in combination on growth of human zr-75-1 breast cancer xenografts in nude mice. Cancer Res. 1999;59:5176-5180.
36. Ludeman SM, Zon G, Egan W. Synthesis and antitumor activity of cyclophosphamide analogues: preparation, hydrolytic studies, and anticancer screening of 5-bromocyclophosphamide, 3,5-dehydrocyclophosphamide, and related systems. J Med Chem. 1979;22:151-158.
37. Boyd VL, Zon G, Himes VL, Stalick JK, Mighell AD, Secor HV. Synthesis and antitumor activity of cyclophosphamide analogues. 3. Preparation, molecular structure determination and anticancer screening of racemic cis- and trans-4-phenylcyclophosphamide. J Med Chem. 1980;23:372-375.
38. Ludeman SM, Boyd VL, Regan JB, Gallo KA, Zon G, Ishii K. Synthesis and antitumor activity of cyclophosphamide analogues. 4. Preparation, kinetic studies, and anticancer screening of "phenylketophosphamide" and similar compounds related to the cyclophosphamide metabolite aldophosphamide. J Med Chem. 1986;29:716-727.
39. Glazman-Kusnierczyk H, Matuszyk J, Radzikowski C. Antitumor activity evaluation of bromine-substituted analogues of ifosfamide. I. Stereodifferentiation of biological effects and selection of the most potent compounds. Immunopharmacol Immunotoxicol. 1992;14:883-911.